Developer docs
API playgroundTry for free, no card

Search company profiles

RECEPTOR.AI

Full company profile

uuid000098b

Namestring
RECEPTOR.AI
Legal namestring
Receptor.ai Inc.
Websiteurl
receptor.ai
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Receptor.AI is a TechBio company providing AI-accelerated preclinical drug discovery services through a multiplatform ecosystem spanning three modality-specific platforms: Small Molecules, Peptides, and Biologics & Proximity Inducers. Founded in Q1 2021 in Kyiv and now headquartered in London with a US headquarters in Cambridge, MA and an R&D facility in Magdeburg, Germany, the company targets pharmaceutical companies (including Top-5 Big Pharma), mid-sized pharma/biotech firms, and academic institutions across North America, Europe, and Asia. Core proprietary technologies include QuorumMap (a multi-objective navigation engine exploring 10^16-scale chemical space), ArtiDock (an AI docking model claimed to outperform AlphaFold), ADMETiQ (predictive evaluation across 80+ ADMET endpoints), StratAI Decision Engine (autonomous project-level orchestration driven by experimental feedback), and AI Pocket Detection for identifying allosteric, cryptic, transient, and hidden binding pockets. The platforms are integrated with specialized experimental laboratories enabling end-to-end drug candidate design from hit identification through lead optimization and preclinical candidate selection.

The company operates a dual revenue model combining project-based collaborative drug discovery services (professional services spanning hit identification, hit-to-lead, lead optimization, and preclinical candidate selection) and a recurring SaaS/platform licensing layer for technology access. Its go-to-market is sales-led and enterprise-focused, with direct engagement via "Request a Demo" CTAs and a dedicated BDR team targeting pharma and biotech partners worldwide. Disclosed commercial traction includes 40+ completed drug discovery projects with an 86% success rate as of Q3 2024, scientific advisory board members with combined delivery of 8 new chemical entities to clinic, and named collaborations with Ono Pharmaceutical, Sareum Holdings, BriaCell Therapeutics, PRISM BioLab, and Lubrizol.

Short descriptiontext

Receptor.AI is a TechBio company offering an AI-native multiplatform drug discovery ecosystem spanning small molecules, peptides, and induced proximity modalities. It serves pharmaceutical, biotechnology, and academic clients globally through project-based services and SaaS access, supported by proprietary QuorumMap, ArtiDock, and ADMETiQ AI models.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, preclinical drug discovery, small molecule design, peptide therapeutics, ADMET prediction
Industry4 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Software Publishers5132
SIC code1 code
  • Services-Computer Integrated Systems Design7373
Product category
AI Drug Discovery Platform
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Collaborative Drug Discovery Services
TypeProfessional Services
Description

Revenue generated through collaborative research partnerships with pharmaceutical companies. Projects span hit identification, hit-to-lead, lead optimization, and preclinical candidate selection. Services are provided on a project basis with direct scientific team engagement.

receptor.ai
2Platform Access and Technology Licensing
TypeSubscription Recurring
Description

Access to AI-powered drug discovery platforms including screening workflows, docking tools, and ADMET prediction systems. SaaS platform established for scalable drug discovery solutions.

receptor.ai
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Receptor.AI operates a multiplatform AI ecosystem for preclinical drug discovery spanning three modality-specific platforms — Small Molecules, Peptides, and Biologics & Proximity Inducers. The platforms integrate proprietary AI models including QuorumMap (chemical space navigation), ArtiDock (AI docking), ADMETiQ (ADMET prediction), and Oracle.AI (virtual screening) to support hit identification, lead optimization, and preclinical candidate selection. The company delivers these capabilities through collaborative drug discovery partnerships and SaaS platform access for pharmaceutical and biotech organizations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 86% project success rate for completed drug discovery projects
+7 more records
Product overview1 text field

Receptor.AI is a TechBio company offering a multiplatform AI ecosystem for preclinical drug discovery across three modality-specific platforms: Small Molecules, Peptides, and Biologics & Proximity Inducers. The modular architecture provides end-to-end drug candidate design capabilities within each platform, orchestrated by Agentic AI systems. Core technologies include QuorumMap for chemical space navigation, ArtiDock for AI-powered protein-ligand docking, ADMETiQ for predictive ADMET evaluation, and Oracle.AI for virtual screening. The platforms are seamlessly integrated with specialized experimental laboratories providing validated workflows from hit identification through lead optimization.

Product and service8 records
1Small Molecule Platform
CategoryAI Drug Discovery Platform
Description

AI-driven drug discovery platform for de novo design of small molecules targeting kinases, GPCRs, ion channels, enzymes, and other protein classes. Includes AI pocket identification (allosteric, hidden, transient, cryptic), automated SAR analysis, multiparametric virtual screening with QuorumMap, selectivity optimization, and ADMET prediction across 80+ endpoints. Used by pharma and biotech discovery teams.

2Peptide Platform
CategoryAI Drug Discovery Platform
Description

AI-guided de novo design and optimization of linear and cyclic peptides for challenging targets including undruggable protein-protein interactions. Features a library of 10K+ non-canonical amino acids, non-peptide blocks, and linkage chemistry with multiparametric optimization for activity, permeability, and oral availability. Used by pharma and biotech drug discovery teams.

3Biologics & Proximity Inducers Platform
CategoryAI Drug Discovery Platform
Description

Platform for designing proximity inducers such as degraders, molecular glues, and PPI disruptors. Enables antibody-based therapeutics including bispecifics, immune cell engagers, and antibody-guided scaffolds. Predicts PPI structures and ternary complexes for both natural and induced PPIs. Targets protein-protein interactions and complex receptor systems.

4QuorumMap
CategoryAI Engine / Optimization Tool
Description

AI-guided navigation system for exploring 10^16-scale chemical space in information-rich batches. Combines multiple docking engines and ADMET models with a multi-parameter reward function that prioritizes compounds by docking quality, ADMET properties, selectivity, drug-likeness, novelty, and diversity. Uses uncertainty + diversity strategy for batch selection.

5ArtiDock
CategoryAI Engine / Docking Tool
Description

Best-in-class AI docking model that outperforms all conventional and AI docking techniques including AlphaFold. Used for ensemble AI docking with target-specific rescoring. Ranked as the world's top-performing molecular docking model.

6ADMETiQ
CategoryAI Engine / ADMET Prediction
Description

Predictive system for ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) evaluation covering 80+ parameters. Includes dedicated BBB (blood-brain barrier) model for predicting CNS permeability. Integrated into optimization workflows for lead compound refinement.

7Oracle.AI
CategoryAI Engine / Virtual Screening
Description

Virtual screening platform combining AI models including ArtiDock with physics-based approaches for identifying promising drug candidates. Uses ensemble docking and knowledge graph analysis for compound prioritization.

8Collaborative Drug Discovery Services
CategoryDrug Discovery Services
Description

Project-based collaborative drug discovery services spanning hit identification, hit-to-lead, lead optimization, and preclinical candidate selection. Delivered through direct scientific team engagement with pharmaceutical and biotech partners on a quote-based enterprise model.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-13
Description

Drug discovery collaboration to develop an integrated AI-navigated platform for discovering orally available small molecules targeting protein-protein interactions, membrane proteins, and complex receptor systems. Combines PRISM's PepMetics chemistry with Receptor.AI's AI navigation engine, initially focusing on metabolic diseases including obesity. Both companies aim to jointly engage pharmaceutical partners.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-20
Description

Collaboration on AI-driven small molecule cancer therapeutics. BriaCell focuses on developing immunotherapies and personalized treatments for cancer with Phase 3 lead candidate Bria-IMT.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-09-01
Description

Collaboration launched Q3 2025 to advance AI-guided peptide innovation for skin care and bioactive peptide discovery.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-08-14
Description

Strategic collaboration for discovery and optimization of blood-brain barrier (BBB)-permeable, isoform-selective TYK2/JAK1 inhibitors for neuroinflammatory conditions including multiple sclerosis and Parkinson's disease. Receptor.AI uses Oracle.AI virtual screening platform with ArtiDock and physics-based approaches. Sareum retains ownership of resulting IP.

5Ono Pharmaceutical (小野薬品工業)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Research collaboration launched Q1 2025 to design novel therapeutics, strengthening Receptor.AI's reach in the Japanese pharma market. Ono is a leader in Japan's innovation ecosystem.

receptor.ai
6Peptide Drug Hunting Consortium (PDHC)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-12-01
Description

Became member of PDHC contributing AI expertise and joining advisory boards. Collaborative initiative for peptide drug discovery.

receptor.ai
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Key partnership established Q1 2024 with major pharmaceutical company concentrating on membrane mitochondrial kinases.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-12-01
Description

Partnership with Nvidia to enhance generative AI capabilities for drug discovery platform development.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

RECEPTOR.AI

AI Drug Discovery Platformreceptor.ai

Receptor.AI is a TechBio company offering an AI-native multiplatform drug discovery ecosystem spanning small molecules, peptides, and induced proximity modalities. It serves pharmaceutical, biotechnology, and academic clients globally through project-based services and SaaS access, supported by proprietary QuorumMap, ArtiDock, and ADMETiQ AI models.

What RECEPTOR.AI does

Receptor.AI is a TechBio company providing AI-accelerated preclinical drug discovery services through a multiplatform ecosystem spanning three modality-specific platforms: Small Molecules, Peptides, and Biologics & Proximity Inducers. Founded in Q1 2021 in Kyiv and now headquartered in London with a US headquarters in Cambridge, MA and an R&D facility in Magdeburg, Germany, the company targets pharmaceutical companies (including Top-5 Big Pharma), mid-sized pharma/biotech firms, and academic institutions across North America, Europe, and Asia. Core proprietary technologies include QuorumMap (a multi-objective navigation engine exploring 10^16-scale chemical space), ArtiDock (an AI docking model claimed to outperform AlphaFold), ADMETiQ (predictive evaluation across 80+ ADMET endpoints), StratAI Decision Engine (autonomous project-level orchestration driven by experimental feedback), and AI Pocket Detection for identifying allosteric, cryptic, transient, and hidden binding pockets. The platforms are integrated with specialized experimental laboratories enabling end-to-end drug candidate design from hit identification through lead optimization and preclinical candidate selection.

The company operates a dual revenue model combining project-based collaborative drug discovery services (professional services spanning hit identification, hit-to-lead, lead optimization, and preclinical candidate selection) and a recurring SaaS/platform licensing layer for technology access. Its go-to-market is sales-led and enterprise-focused, with direct engagement via "Request a Demo" CTAs and a dedicated BDR team targeting pharma and biotech partners worldwide. Disclosed commercial traction includes 40+ completed drug discovery projects with an 86% success rate as of Q3 2024, scientific advisory board members with combined delivery of 8 new chemical entities to clinic, and named collaborations with Ono Pharmaceutical, Sareum Holdings, BriaCell Therapeutics, PRISM BioLab, and Lubrizol.

RECEPTOR.AI firmographics

Firmographics
Name
RECEPTOR.AI
Legal name
Receptor.ai Inc.
Website
https://receptor.ai
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Receptor.AI is a TechBio company offering an AI-native multiplatform drug discovery ecosystem spanning small molecules, peptides, and induced proximity modalities. It serves pharmaceutical, biotechnology, and academic clients globally through project-based services and SaaS access, supported by proprietary QuorumMap, ArtiDock, and ADMETiQ AI models.
Ownership category
akta.pro rank

RECEPTOR.AI industry classification

Industry
Product category
AI Drug Discovery Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (5132)
SIC
Services-Computer Integrated Systems Design (7373)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • AI drug discovery
  • Preclinical drug discovery
  • Small molecule design
  • Peptide therapeutics
  • ADMET prediction

Where RECEPTOR.AI is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices3 records

Markets served

RECEPTOR.AI business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Collaborative Drug Discovery Services: Revenue generated through collaborative research partnerships with pharmaceutical companies. Projects span hit identification, hit-to-lead, lead optimization, and preclinical candidate selection. Services are provided on a project basis with direct scientific team engagement.
  2. Platform Access and Technology Licensing: Access to AI-powered drug discovery platforms including screening workflows, docking tools, and ADMET prediction systems. SaaS platform established for scalable drug discovery solutions.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

RECEPTOR.AI product offering

Product offering

Core offering

Receptor.AI operates a multiplatform AI ecosystem for preclinical drug discovery spanning three modality-specific platforms — Small Molecules, Peptides, and Biologics & Proximity Inducers. The platforms integrate proprietary AI models including QuorumMap (chemical space navigation), ArtiDock (AI docking), ADMETiQ (ADMET prediction), and Oracle.AI (virtual screening) to support hit identification, lead optimization, and preclinical candidate selection. The company delivers these capabilities through collaborative drug discovery partnerships and SaaS platform access for pharmaceutical and biotech organizations.

Product overview

Receptor.AI is a TechBio company offering a multiplatform AI ecosystem for preclinical drug discovery across three modality-specific platforms: Small Molecules, Peptides, and Biologics & Proximity Inducers. The modular architecture provides end-to-end drug candidate design capabilities within each platform, orchestrated by Agentic AI systems. Core technologies include QuorumMap for chemical space navigation, ArtiDock for AI-powered protein-ligand docking, ADMETiQ for predictive ADMET evaluation, and Oracle.AI for virtual screening. The platforms are seamlessly integrated with specialized experimental laboratories providing validated workflows from hit identification through lead optimization.

Differentiator

Problem solved

Functional benefit

Products and services

  • Small Molecule Platform AI-driven drug discovery platform for de novo design of small molecules targeting kinases, GPCRs, ion channels, enzymes, and other protein classes. Includes AI pocket identification (allosteric, hidden, transient, cryptic), automated SAR analysis, multiparametric virtual screening with QuorumMap, selectivity optimization, and ADMET prediction across 80+ endpoints. Used by pharma and biotech discovery teams.
  • Peptide Platform AI-guided de novo design and optimization of linear and cyclic peptides for challenging targets including undruggable protein-protein interactions. Features a library of 10K+ non-canonical amino acids, non-peptide blocks, and linkage chemistry with multiparametric optimization for activity, permeability, and oral availability. Used by pharma and biotech drug discovery teams.
  • Biologics & Proximity Inducers Platform Platform for designing proximity inducers such as degraders, molecular glues, and PPI disruptors. Enables antibody-based therapeutics including bispecifics, immune cell engagers, and antibody-guided scaffolds. Predicts PPI structures and ternary complexes for both natural and induced PPIs. Targets protein-protein interactions and complex receptor systems.
  • QuorumMap AI-guided navigation system for exploring 10^16-scale chemical space in information-rich batches. Combines multiple docking engines and ADMET models with a multi-parameter reward function that prioritizes compounds by docking quality, ADMET properties, selectivity, drug-likeness, novelty, and diversity. Uses uncertainty + diversity strategy for batch selection.
  • ArtiDock Best-in-class AI docking model that outperforms all conventional and AI docking techniques including AlphaFold. Used for ensemble AI docking with target-specific rescoring. Ranked as the world's top-performing molecular docking model.
  • ADMETiQ Predictive system for ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) evaluation covering 80+ parameters. Includes dedicated BBB (blood-brain barrier) model for predicting CNS permeability. Integrated into optimization workflows for lead compound refinement.
  • Oracle.AI Virtual screening platform combining AI models including ArtiDock with physics-based approaches for identifying promising drug candidates. Uses ensemble docking and knowledge graph analysis for compound prioritization.
  • Collaborative Drug Discovery Services Project-based collaborative drug discovery services spanning hit identification, hit-to-lead, lead optimization, and preclinical candidate selection. Delivered through direct scientific team engagement with pharmaceutical and biotech partners on a quote-based enterprise model.

Quantifiable outcome

  • 86% project success rate for completed drug discovery projects
  • +7 more outcomes

Companies that use RECEPTOR.AI

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles4 records

RECEPTOR.AI technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature8 records

RECEPTOR.AI partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • PRISM BioLabcoreStrategic or Co-development Partner · 13 March 2026Drug discovery collaboration to develop an integrated AI-navigated platform for discovering orally available small molecules targeting protein-protein interactions, membrane proteins, and complex receptor systems. Combines PRISM's PepMetics chemistry with Receptor.AI's AI navigation engine, initially focusing on metabolic diseases including obesity. Both companies aim to jointly engage pharmaceutical partners.
  • BriaCell Therapeutics Corp.coreStrategic or Co-development Partner · 20 November 2025Collaboration on AI-driven small molecule cancer therapeutics. BriaCell focuses on developing immunotherapies and personalized treatments for cancer with Phase 3 lead candidate Bria-IMT.
  • LubrizolminorStrategic or Co-development Partner · 1 September 2025Collaboration launched Q3 2025 to advance AI-guided peptide innovation for skin care and bioactive peptide discovery.
  • Sareum Holdings plccoreStrategic or Co-development Partner · 14 August 2025Strategic collaboration for discovery and optimization of blood-brain barrier (BBB)-permeable, isoform-selective TYK2/JAK1 inhibitors for neuroinflammatory conditions including multiple sclerosis and Parkinson's disease. Receptor.AI uses Oracle.AI virtual screening platform with ArtiDock and physics-based approaches. Sareum retains ownership of resulting IP.
  • Ono Pharmaceutical (小野薬品工業)coreStrategic or Co-development Partner · 1 January 2025Research collaboration launched Q1 2025 to design novel therapeutics, strengthening Receptor.AI's reach in the Japanese pharma market. Ono is a leader in Japan's innovation ecosystem.
  • Peptide Drug Hunting Consortium (PDHC)minorStrategic or Co-development Partner · 1 December 2024Became member of PDHC contributing AI expertise and joining advisory boards. Collaborative initiative for peptide drug discovery.
  • Major Pharmaceutical Company (Membrane Mitochondrial Kinases)coreStrategic or Co-development Partner · 1 January 2024Key partnership established Q1 2024 with major pharmaceutical company concentrating on membrane mitochondrial kinases.
  • NvidiacoreTechnology or Integration · 1 December 2023Partnership with Nvidia to enhance generative AI capabilities for drug discovery platform development.

Scale indicators9 records

Recent moves9 records

Expansion highlights7 records

RECEPTOR.AI competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key highlights7 records

Customer concentration

RECEPTOR.AI social profiles

Digital presence

RECEPTOR.AI financial estimates

Financial estimate

Revenue estimate

Valuation estimate

RECEPTOR.AI leadership team

Management profile

Number of profiles

Profiles13 records

RECEPTOR.AI funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

RECEPTOR.AI M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RECEPTOR.AI

What does RECEPTOR.AI do?

Receptor.AI operates a multiplatform AI ecosystem for preclinical drug discovery spanning three modality-specific platforms — Small Molecules, Peptides, and Biologics & Proximity Inducers. The platforms integrate proprietary AI models including QuorumMap (chemical space navigation), ArtiDock (AI docking), ADMETiQ (ADMET prediction), and Oracle.AI (virtual screening) to support hit identification, lead optimization, and preclinical candidate selection. The company delivers these capabilities through collaborative drug discovery partnerships and SaaS platform access for pharmaceutical and biotech organizations.

Is RECEPTOR.AI a public or private company?

RECEPTOR.AI is a private company. It is classified as venture growth investor backed and is currently operating.

When was RECEPTOR.AI founded?

RECEPTOR.AI was founded in 2021. It employs 11 to 50 people.

Where is RECEPTOR.AI based?

RECEPTOR.AI is headquartered in Cambridge, United States, in the North America region.

How does RECEPTOR.AI make money?

Two revenue lines are on record. Collaborative Drug Discovery Services are the primary driver. The others are platform Access and Technology Licensing.

Does RECEPTOR.AI have an API?

No public API is recorded for RECEPTOR.AI.

What industry is RECEPTOR.AI in?

RECEPTOR.AI's product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 7373.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
B2B SaaS BlogReceptor.ai Revenue 2024: $3.8M ARRReceptor.AI is a TechBio company developing AI-powered platforms for drug discovery, including small molecules, peptides, and drug conjugates. The company reports over 40 projects with an 85% success rate and partners with major biotech and pharma firms.The Pharma LetterReceptor.AI, Sethera team up on AI-driven peptide discoveryReceptor.AI and Sethera Therapeutics formed a research alliance combining computational modeling with peptide library screening to identify potential drugs for hard-to-drug targets. Sethera will use its enzymatic polymacrocyclization platform and encoded peptide libraries, which the company says can contain trillions of candidates.EIN PresswireSethera Therapeutics and Receptor.AI Form Integrated Discovery Alliance for AI-Guided Polymacrocyclic Peptide MedicinesSethera Therapeutics and Receptor.AI announced a strategic research collaboration to combine Sethera's enzymatic polymacrocyclic peptide platform with Receptor.AI's AI and physics-based modeling. The alliance will generate and screen peptide libraries, then use computational analysis to prioritize and optimize candidates, aiming to reduce design cycles. The initial program targets a hard-to-drug target, with further collaborations planned.The Pharma LetterPRISM BioLab and Receptor.AI collaborate on molecule discoveryPRISM BioLab and Receptor.AI signed a drug discovery collaboration to develop an AI-navigated, physics-guided platform for small molecules targeting intracellular PPIs, membrane proteins, and complex receptors. The partnership combines PRISM's PepMetics chemistry with Receptor.AI's AI engine, focusing on metabolic diseases like obesity.MorningstarPRISM BioLab and Receptor.AI Announce Drug Discovery Collaboration AgreementPRISM BioLab and Receptor.AI have entered into a drug discovery collaboration agreement to develop an integrated, AI-navigated, physics-guided platform for discovering orally available small molecules targeting protein-protein interactions, membrane proteins, and complex receptor systems. The collaboration combines PRISM's PepMetics chemistry with Receptor.AI's multi-objective AI navigation engine, initially focusing on metabolic diseases including obesity. The companies aim not only to generate clinical candidates but also to jointly engage pharmaceutical partners and showcase their combined technologies as a basis for future collaborative opportunities.PrtimesPRISM BioLabとReceptor.AI、創薬提携契約締結のお知らせPRISM BioLab Co., Ltd. and Receptor.AI Inc. have announced a drug discovery partnership to develop small molecule drugs targeting protein-protein interactions (PPI) and membrane proteins, combining PRISM's PepMetics® technology with Receptor.AI's AI-powered molecular design platform. The collaboration will initially focus on metabolic diseases, aiming to generate innovative hit compounds, lead compounds, and clinical candidate compounds through the integration of both companies' proprietary technologies. Both companies share a philosophy of "challenging drug discovery with new approaches" and intend to build a data-driven optimized drug discovery cycle while seeking collaborative research opportunities with pharmaceutical companies.The Manila TimesBriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer TherapeuticsBriaCell's subsidiary BriaPro initiated a research collaboration with Receptor.AI to design anti-cancer isoform-selective kinase inhibitors for multiple indications. The partnership aims to expand BriaPro's small-molecule pipeline and accelerate development of therapeutics with improved efficacy and safety.GlobeNewswireBriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer TherapeuticsBriaCell's subsidiary BriaPro initiated a collaboration with Receptor.AI to design isoform-selective anti-cancer kinase inhibitors. The partnership aims to expand BriaPro's small-molecule pipeline and accelerate development of therapeutics with improved efficacy and safety.Stock TitanBriaCell, Receptor.AI Partner on AI Cancer Drug DiscoveryBriaCell's subsidiary BriaPro initiated a collaboration with Receptor.AI to design isoform-selective anti-cancer kinase inhibitors. The partnership aims to expand BriaPro's small-molecule pipeline and accelerate next-generation therapeutics with improved efficacy and safety.YahooOragenics partners Receptor.AI for brain health candidate portfolioOragenics partnered with Receptor.AI to use AI modeling to identify receptor binding profiles for new brain health compounds added in 2023. The collaboration aims to streamline lab validation and support development for conditions like Parkinson's and Alzheimer's. Oragenics is progressing Phase IIa trials of ONP-002 in Australia, with Phase IIb planned in the US.